Ultrastructural analysis of dermal fibroblasts in mucopolysaccharidosis type I: Effects of enzyme replacement therapy and hematopoietic cell transplantation

Ultrastructural Pathology

Volumn 34, Issue 3, 2010, Pages 126-132

  Cox Brinkman, Josanne ^a   Van Den Bergh Weerman, Marius A ^a   Wijburg, Frits A ^a   Aerts, Johannes M F G ^a   Florquin, Sandrine ^a   Van Der Lee, Johanna H ^a   Hollak, Carla E M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN;

ADOLESCENT; ADULT; BIOPSY; CELL VACUOLE; CHILD; CONFERENCE PAPER; DERMIS; ENZYME REPLACEMENT; FIBROBLAST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HURLER SYNDROME; INFANT; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; ULTRASTRUCTURE; URINE;

ADOLESCENT; ADULT; BIOPSY; CHILD; COMBINED MODALITY THERAPY; DERMIS; ENZYME REPLACEMENT THERAPY; FIBROBLASTS; GLYCOSAMINOGLYCANS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MUCOPOLYSACCHARIDOSIS I; VACUOLES;

EID: 77952268941     PISSN: 01913123     EISSN: 15210758     Source Type: Journal    
DOI: 10.3109/01913121003648485     Document Type: Conference Paper

References (20)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2001: 3421-3452.
2. Peters C, Shapiro EG, Anderson J, et al. Hurler syndrome II: outcome of HLA genotypically identical sibling and HLAhaploidentical related donor bone marrow transplantation in fifty-four children. Blood. 1998;91:2601-2608.
3. Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (Laronidase). J Pediatr. 2004;144:581-588.
4. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. New Engl J Med. 2001;344:182-188.
5. Shull RM, Kakkis ED, McEntee MF, Kania SA, Jonas AJ, Neufeld EF. Enzyme replacement in a canine model of Hurler syndrome. Proc Natl Acad Sci U S A. 1994;91:12937-12941.
6. Kakkis ED, McEntee MF, Schmidtchen A, et al. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis. Biochem Mol Med. 1996;58:156-167.
7. Conrad GW, Sherman D, Dorfman A. An ultrastructural comparison of normal and Hurler syndrome dermal fibroblasts. Pediatr Res. 1972;6:563-575.
8. DeCloux RJ, Friederici HH. Ultrastructural studies of the skin in Hurler's syndrome. Arch Pathol. 1969;88:350-358.
9. Yamano T, Shimada M, Okada S, Yutaka T, Yabuuchi H, Nakao Y. Electron microscopic examination of skin and conjunctival biopsy specimens in neuronal storage diseases. Brain Dev. 1979;1:16-25.
10. Costa M, Valero JG, Navarro C. Stereological and morphometric analysis of dermal fibroblasts before and after bone-marrow transplantation in a case of mucopolysaccharidosis-I Scheie phenotype. Acta Neuropathol. 1993;86:21-28.
11. Navarro C, Dominguez C, Costa M, Ortega JJ. Bone marrow transplant in a case of mucopolysaccharidosis I Scheie phenotype: skin ultrastructure before and after transplantation. Acta Neuropathol (Berl). 1991;82:33-38.
12. Cox-Brinkman J, Boelens JJ, Wraith JE, et al. Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. Bone Marrow Transplant. 2006;38:17-21.
13. de Jong JG, Wevers RA, Laarakkers C, Poorthuis BJ. Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. Clin Chem. 1989;35:1472-1477.
14. Fuller M, Rozaklis T, Ramsay SL, Hopwood JJ, Meikle PJ. Disease-specific markers for the mucopolysaccharidoses. Pediatr Res. 2004;56:733-738.
15. Chatterjee S, Gupta P, Pyeritz RE, Kwiterovich PO Jr. Immunohistochemical localization of glycosphingolipid in urinary renal tubular cells in Fabry's disease. Am J Clin Pathol. 1984;82:24-28.
16. Whitfield PD, Calvin J, Hogg S, et al. Monitoring enzyme replacement therapy in Fabry disease-role of urine globotriaosylceramide. J Inherit Metab Dis. 2005;28:21-33.
17. Resnick JM, Krivit W, Snover DC, et al. Pathology of the liver in mucopolysaccharidosis: light and electron microscopic assessment before and after bone marrow transplantation. Bone Marrow Transplant. 1992;10:273-280.
18. Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 2004;75:65-74.
19. Cox-Brinkman J, Smeulders MJ, Hollak CE, Wijburg FA. Restricted upper extremity range of motion in mucopolysaccharidosis type I: no response to one year of enzyme replacement therapy. J Inherit Metab Dis. 2007;30:47-50.
20. Sifuentes M, Doroshow R, Hoft R, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab. 2007;90:171-180.